Identification_of_regulators_of_BCL11A_with_CRISPR_CAS9_screens-sc-5030
Identification_of_regulators_of_BCL11A_with_CRISPR_CAS9_screens
We have performed CRISPR/Cas9 screen with a genome wide murine sgRNA library in breast cancer cell line selected in vivo after different treatment to study BCL11A regulation. DNA pellet of different amount and concentration will be provided to be processed thorugh CGP pipeline for sgRNA sequencing.  DNA will be processed by CGP pipeline (2 nested PCR) and then sequenced to identify the 19bp of the sgRNA and quantify their representation. Sequencing will be performed on PCR products from the amplification of gRNA segments introduced into cell lines (commercial murine cell lines, no HMDMC required). Cellular DNA or RNA are not sequenced. This data is defined as "Other Biological/Biochemical Assay Data" under the WTSI datasharing guidelines and consequently will be released at the time of publication and/or through faculty websites.  PLEASE SEQUENCE WITH THE CUSTOM 19BP APPROACH AND OLIGOS USED FOR KOSUKE YUSA LIBRARIES (from Adams' group stock)
reast cancer is the second most common cancer worldwide and the leading cause of cancer death in women. Among the different subtypes, triple negative breast cancer (TNBC) is associated with the poorest prognosis. As there is a lack of targeted therapy for it, a better understanding of the molecular and developmental dynamics of TNBC is paramount. We have previously identified BCL11A as a key TNBC gene. By using CRISPR/Cas9 genome-wide screenings, we are aiming at identifying positive and negative regulators of BCL11A in TNBC. The results will help us to identify potential candidates for targeted therapy.